{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2
  ],
  "modelUsed": "gemini-3-flash-preview",
  "metadata": {
    "studyName": "A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN CO",
    "titles": [
      {
        "id": "title_1",
        "text": "A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA®) VERSUS SUNITINIB (SUTENT®) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA",
        "type": {
          "code": "Official Study Title",
          "codeSystem": "USDM",
          "decode": "Official Study Title"
        },
        "instanceType": "StudyTitle"
      },
      {
        "id": "title_2",
        "text": "Renal Cell Carcinoma − Javelin Renal 101",
        "type": {
          "code": "Brief Study Title",
          "codeSystem": "USDM",
          "decode": "Brief Study Title"
        },
        "instanceType": "StudyTitle"
      },
      {
        "id": "title_3",
        "text": "Javelin Renal 101",
        "type": {
          "code": "Study Acronym",
          "codeSystem": "USDM",
          "decode": "Study Acronym"
        },
        "instanceType": "StudyTitle"
      }
    ],
    "identifiers": [
      {
        "id": "sid_1",
        "text": "B9991003",
        "scopeId": "org_1",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "SponsorProtocolNumber",
          "codeSystem": "USDM",
          "decode": "Sponsor Protocol Number"
        }
      },
      {
        "id": "sid_2",
        "text": "2015-002429-20",
        "scopeId": "org_eudract",
        "instanceType": "StudyIdentifier",
        "identifierType": {
          "code": "EudraCT",
          "codeSystem": "USDM",
          "decode": "EudraCT Number"
        }
      }
    ],
    "organizations": [
      {
        "id": "org_1",
        "name": "Sponsor",
        "type": {
          "id": "365ff2a3-add1-4696-af2a-f8a87359e6a4",
          "code": "C54086",
          "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "codeSystemVersion": "25.01d",
          "decode": "Pharmaceutical Company",
          "instanceType": "Code"
        },
        "identifier": "Sponsor",
        "identifierScheme": "DUNS",
        "instanceType": "Organization"
      }
    ],
    "roles": [
      {
        "id": "role_1",
        "name": "Sponsor",
        "code": {
          "code": "Sponsor",
          "codeSystem": "USDM",
          "decode": "Sponsor"
        },
        "organizationIds": [
          "org_1"
        ],
        "instanceType": "StudyRole"
      }
    ],
    "indications": [
      {
        "id": "ind_1",
        "name": "Advanced Renal Cell Carcinoma",
        "isRareDisease": false,
        "instanceType": "Indication",
        "description": "First-line treatment of patients with advanced renal cell carcinoma"
      }
    ],
    "studyPhase": {
      "code": "Phase3",
      "codeSystem": "USDM",
      "decode": "Phase3"
    },
    "studyType": "Interventional"
  },
  "rawResponse": {
    "titles": [
      {
        "id": "title_1",
        "text": "A PHASE 3, MULTINATIONAL, RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AXITINIB (INLYTA®) VERSUS SUNITINIB (SUTENT®) MONOTHERAPY IN THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA",
        "type": {
          "code": "OfficialStudyTitle",
          "codeSystem": "http://www.cdisc.org/USDM/titleType",
          "decode": "Official Study Title"
        },
        "instanceType": "StudyTitle"
      },
      {
        "id": "title_2",
        "text": "Renal Cell Carcinoma − Javelin Renal 101",
        "type": {
          "code": "BriefStudyTitle",
          "codeSystem": "http://www.cdisc.org/USDM/titleType",
          "decode": "Brief Study Title"
        },
        "instanceType": "StudyTitle"
      },
      {
        "id": "title_3",
        "text": "Javelin Renal 101",
        "type": {
          "code": "StudyAcronym",
          "codeSystem": "http://www.cdisc.org/USDM/titleType",
          "decode": "Study Acronym"
        },
        "instanceType": "StudyTitle"
      }
    ],
    "identifiers": [
      {
        "id": "sid_1",
        "text": "B9991003",
        "identifierType": "SponsorProtocolNumber",
        "issuingOrganization": "Sponsor",
        "instanceType": "StudyIdentifier"
      },
      {
        "id": "sid_2",
        "text": "2015-002429-20",
        "identifierType": "EudraCT",
        "issuingOrganization": "EudraCT",
        "instanceType": "StudyIdentifier"
      }
    ],
    "organizations": [
      {
        "id": "org_1",
        "name": "Sponsor",
        "type": {
          "code": "Sponsor",
          "codeSystem": "http://www.cdisc.org/USDM/organizationType",
          "decode": "Sponsor"
        },
        "role": "Sponsor",
        "instanceType": "Organization"
      }
    ],
    "studyPhase": {
      "code": "Phase3",
      "codeSystem": "http://www.cdisc.org/USDM/studyPhase",
      "decode": "Phase 3"
    },
    "studyType": "Interventional",
    "indication": {
      "id": "ind_1",
      "name": "Advanced Renal Cell Carcinoma",
      "description": "First-line treatment of patients with advanced renal cell carcinoma",
      "instanceType": "Indication"
    }
  }
}